The Journal of Immunology, Vol 143, Issue 4 1149-1154, Copyright © 1989 by American Association of Immunologists

ARTICLES

Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV

S Lederman, R Gulick and L Chess
Department of Medicine, Columbia University, College of Physicians and Surgeons, NY 10032.

Dextran sulfate, heparin, and certain other sulfated polysaccharides potently inhibit the adsorption of HIV to CD4+ cells. The mechanism of this inhibition is unclear and, specifically, it is unknown if these agents act at the level of CD4-gp120 binding. For example, previous reports have demonstrated that dextran sulfate does not inhibit the cell surface binding of anti-CD4 mAb known to be directed at the gp120 binding site. In order to confirm and extend these observations, in the present study, it was shown that dextran sulfate does not inhibit the binding of OKT4A, OKT4C, Leu3a, or B66.6 to CD4+ cells as measured by cytofluorography. Next, recombinant forms of CD4 (rT4) and gp120 (rgp120) were utilized to directly study their molecular interaction in the absence of other viral or cellular structures. Reciprocal solid phase ELISA assays were developed to study directly the effects of sulfated polysaccharides on the binding of rT4 to immobilized rgp120 and vice versa. Dextran sulfate, heparin, and fucoidan, but not chondroitin sulfate, inhibited the binding of rgp120 to rT4. Importantly, dextran sulfate and heparin pre-treatment of immobilized rT4, but not immobilized rgp120, inhibited rT4-rgp120 binding. Taken together, these data suggest that while both sulfated polysaccharides and anti-CD4 mAb inhibit gp120 binding, the sulfated polysaccharides interact with sites on CD4 that are distinct from those with which the antibodies bind.

This article has been cited by other articles:

				C. Gurer, A. Hoglund, S. Hoglund, and J. Luban ATP{gamma}S Disrupts Human Immunodeficiency Virus Type 1 Virion Core Integrity J. Virol., May 1, 2005; 79(9): 5557 - 5567. [Abstract] [Full Text] [PDF]

				C. Gurer, L. Berthoux, and J. Luban Covalent Modification of Human Immunodeficiency Virus Type 1 p6 by SUMO-1 J. Virol., January 15, 2005; 79(2): 910 - 917. [Abstract] [Full Text] [PDF]

				P. J. Budge, Y. Li, J. A. Beeler, and B. S. Graham RhoA-Derived Peptide Dimers Share Mechanistic Properties with Other Polyanionic Inhibitors of Respiratory Syncytial Virus (RSV), Including Disruption of Viral Attachment and Dependence on RSV G J. Virol., May 15, 2004; 78(10): 5015 - 5022. [Abstract] [Full Text] [PDF]

				E. G. Cormier, M. Persuh, D. A. D. Thompson, S. W. Lin, T. P. Sakmar, W. C. Olson, and T. Dragic Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120 PNAS, May 23, 2000; 97(11): 5762 - 5767. [Abstract] [Full Text] [PDF]

				C. J. Ianelli, R. DeLellis, and D. A. Thorley-Lawson CD48 Binds to Heparan Sulfate on the Surface of Epithelial Cells J. Biol. Chem., September 4, 1998; 273(36): 23367 - 23375. [Abstract] [Full Text] [PDF]

				C. Stein and Y. Cheng Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science, August 20, 1993; 261(5124): 1004 - 1012. [Abstract] [PDF]